7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases
申请人:——
公开号:US20040102447A1
公开(公告)日:2004-05-27
Pteridine compounds of formula (I) in which R
1
, R
2
, R
3
and R
4
are as specified in the claims, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases such as psoriasis, rheumatoid arthritis, diseases in which angiogenesis is assocated with raised CXCR2 chemokine levels (diabetic retinopathy) and COPD. The compounds are ligands for chemokine receptors and medical indications mentioned in the description include: diseases of the respiratory tract (COPDD, asthma, bronchitis, rhinitis, fibroid lung, pneumonia, etc.), diseases of the bones and joints (arthritis, etc.), skin-diseases (psoriasis, etc), diseases of the gastrointestinal tract, diseases in other tissues and systemic disease (multipe sclerosis, atherosclerosis, AIDS, type 1 diabetes, leprosy, sepsis, etc.), allograft rejection, cancers, cystic fibrosis, stroke, burn wounds, skin ulcers, reproductive disease and more.
式(I)的蝶啶化合物,其中R1、R2、R3和R4如权利要求中所定义,用于其制备的方法和中间体,含有它们的药物组合物,以及它们在治疗如牛皮癣、类风湿性关节炎、与升高的CXCR2趋化因子水平相关的血管生成疾病(糖尿病性视网膜病变)和慢性阻塞性肺病(COPD)等炎症性疾病中的用途。这些化合物是趋化因子受体的配体,描述中提到的医疗适应症包括:呼吸道疾病(COPD、哮喘、支气管炎、鼻炎、纤维化肺、肺炎等)、骨关节疾病(关节炎等)、皮肤病(牛皮癣等)、胃肠道疾病、其他组织疾病和全身性疾病(多发性硬化症、动脉粥样硬化、艾滋病、1型糖尿病、麻风病、败血症等)、异体移植排斥、癌症、囊性纤维化、中风、烧伤伤口、皮肤溃疡、生殖疾病等。